Drug intelligence / Profile preview

oxytocin + ergonovine

Development stage
Phase 4
Modality
Small Molecules, Peptides
Administration
Intramuscular
01

Overview

Oxytocin + ergonovine is a fixed-dose combination drug used in obstetrics for the active management of the third stage of labor and for the prevention and treatment of postpartum hemorrhage due to uterine atony. The combination contains synthetically produced oxytocin, a hypothalamic hormone that stimulates uterine smooth muscle contraction via activation of oxytocin receptors, and ergonovine (also known as ergometrine), an ergot alkaloid that acts as an agonist at alpha-adrenergic, dopaminergic, and serotonin (5-HT2) receptors to induce sustained uterine contractions and vasoconstriction. This dual mechanism provides both rapid onset (from oxytocin) and prolonged action (from ergonovine), reducing blood loss after childbirth. The drug is administered by intramuscular injection immediately after delivery or following placental expulsion[1][6][9][10].

Brand names
Syntometrine
Other names
oxytocin/ergometrineoxytocin + ergometrineergometrine + oxytocin
02

Targets

HTR2A (Serotonin receptor 5-HT2A)ADRA1A (α1A)DRD2 (Dopamine D2 Receptor)Oxytocin receptorADRA1 (Alpha-1 adrenergic receptor family)

Beyond the preview

Go deeper on oxytocin + ergonovine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on oxytocin + ergonovine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call